Literature DB >> 17971791

Reduced cerebral fluoro-L-dopamine uptake in adult patients suffering from phenylketonuria.

Christian Landvogt1, Eugen Mengel, Peter Bartenstein, Hans Georg Buchholz, Mathias Schreckenberger, Thomas Siessmeier, Armin Scheurich, Reinhold Feldmann, Josef Weglage, Paul Cumming, Fred Zepp, Kurt Ullrich.   

Abstract

Deficiency of phenylalanine hydroxylase activity in phenylketonuria (PKU) causes an excess of phenylalanine (Phe) throughout the body, predicting impaired synthesis of catecholamines in the brain. To test this hypothesis, we used positron emission tomography (PET) to measure the utilization of 6-[18F]fluoro-L-DOPA [corrected] (FDOPA) in the brain of adult patients suffering from PKU and in healthy controls. Dynamic 2-h long FDOPA emission recordings were obtained in seven adult PKU patients (five females, two males; age: 21 to 27 years) with elevated serum Phe levels, but lacking neurologic deficits. Seven age-matched, healthy volunteers were imaged under identical conditions. The utilization of FDOPA in striatum was calculated by linear graphical analysis (k3S, min(-1)), with cerebellum serving as a nonbinding reference region. The time to peak activity in all brain time-radioactivity curves was substantially delayed in the PKU patients relative to the control group. The mean magnitude of k3S in the striatum of the PKU patients (0.0052+/-0.0004 min(-1)) was significantly lower than in the control group (0.0088+/-0.0009 min(-1)) (P<0.001). There was no significant correlation between individual serum Phe levels and k3S. The unidirectional clearance of FDOPA to brain was impaired in adult patients suffering from PKU, presumably reflecting the competitive inhibition of the large neutral amino acid carrier by Phe. Assuming this competition to be spatially uniform, the relationship between striatum and cerebellum time-activity curves additionally suggests inhibition of DOPA efflux, possibly also due to competition from Phe. The linear graphical analysis shows reduced k3S in striatum, indicating reduced DOPA decarboxylase activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17971791     DOI: 10.1038/sj.jcbfm.9600571

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  17 in total

1.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

2.  Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.

Authors:  Emily A Sawin; Sangita G Murali; Denise M Ney
Journal:  Mol Genet Metab       Date:  2014-02-08       Impact factor: 4.797

Review 3.  Phenylketonuria Pathophysiology: on the Role of Metabolic Alterations.

Authors:  Patrícia Fernanda Schuck; Fernanda Malgarin; José Henrique Cararo; Fabiola Cardoso; Emilio Luiz Streck; Gustavo Costa Ferreira
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

4.  Phenylketonuria: brain phenylalanine concentrations relate inversely to cerebral protein synthesis.

Authors:  Martijn J de Groot; Paul E Sijens; Dirk-Jan Reijngoud; Anne M Paans; Francjan J van Spronsen
Journal:  J Cereb Blood Flow Metab       Date:  2014-10-29       Impact factor: 6.200

Review 5.  New frontiers in neuroimaging applications to inborn errors of metabolism.

Authors:  Morgan J Prust; Andrea L Gropman; Natalie Hauser
Journal:  Mol Genet Metab       Date:  2011-06-30       Impact factor: 4.797

6.  Host conditioning and rejection monitoring in hepatocyte transplantation in humans.

Authors:  Kyle A Soltys; Kentaro Setoyama; Edgar N Tafaleng; Alejandro Soto Gutiérrez; Jason Fong; Ken Fukumitsu; Taichiro Nishikawa; Masaki Nagaya; Rachel Sada; Kimberly Haberman; Roberto Gramignoli; Kenneth Dorko; Veysel Tahan; Alexandra Dreyzin; Kevin Baskin; John J Crowley; Mubina A Quader; Melvin Deutsch; Chethan Ashokkumar; Benjamin L Shneider; Robert H Squires; Sarangarajan Ranganathan; Miguel Reyes-Mugica; Steven F Dobrowolski; George Mazariegos; Rajavel Elango; Donna B Stolz; Stephen C Strom; Gerard Vockley; Jayanta Roy-Chowdhury; Marilia Cascalho; Chandan Guha; Rakesh Sindhi; Jeffrey L Platt; Ira J Fox
Journal:  J Hepatol       Date:  2016-12-24       Impact factor: 25.083

7.  Parkinsonism in phenylketonuria: a consequence of dopamine depletion?

Authors:  Marieke Velema; Erik Boot; Marc Engelen; Carla Hollak
Journal:  JIMD Rep       Date:  2015-01-23

Review 8.  Genetic etiology and clinical challenges of phenylketonuria.

Authors:  Nasser A Elhawary; Imad A AlJahdali; Iman S Abumansour; Ezzeldin N Elhawary; Nagwa Gaboon; Mohammed Dandini; Abdulelah Madkhali; Wafaa Alosaimi; Abdulmajeed Alzahrani; Fawzia Aljohani; Ehab M Melibary; Osama A Kensara
Journal:  Hum Genomics       Date:  2022-07-19       Impact factor: 6.481

9.  A Retrospective Case Series Analysis of the Relationship Between Phenylalanine: Tyrosine Ratio and Cerebral Glucose Metabolism in Classical Phenylketonuria and Hyperphenylalaninemia.

Authors:  Colm J McGinnity; Daniela A Riaño Barros; Eric Guedj; Nadine Girard; Christopher Symeon; Helen Walker; Sally F Barrington; Mary Summers; Mervi Pitkanen; Yusof Rahman
Journal:  Front Neurosci       Date:  2021-06-17       Impact factor: 4.677

10.  A Pilot Study of Fluorodeoxyglucose Positron Emission Tomography Findings in Patients with Phenylketonuria before and during Sapropterin Supplementation.

Authors:  Can Ficicioglu; Jacob G Dubroff; Nina Thomas; Paul R Gallagher; Jessica Burfield; Christie Hussa; Rebecca Randall; Hongming Zhuang
Journal:  J Clin Neurol       Date:  2013-07-01       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.